Overview
Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients
Status:
Unknown status
Unknown status
Trial end date:
2017-01-01
2017-01-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Cutaneous leishmaniasis (CL) is endemic in Israel and is caused by Leishmania major or Leishmania tropica. CL is usually a benign disease and limited to the skin. One of the local treatment available is intralesional (IL) Pentostam injection. During the current study the investigators will monitor the adverse effects of this treatment and will follow up the recovery of the lesions after Pentostam injections.Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Sheba Medical CenterTreatments:
Antimony Sodium Gluconate
Criteria
Inclusion Criteria:- Cutaneous leishmaniasis patients
- Treatment by IL Pentostam
- Age above 18 years
Exclusion Criteria:
- Children and pregnant women will not participate in the study